Sastravi (carbidopa levodopa entacapone): Reviews and patient testimonials
Back to the list of medications
Medication indications
Sastravi 100mg/25mg/200mg Film-coated Tablets
Sastravi is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
Sastravi 125mg/31.25mg/200mg Film-coated Tablets
Sastravi is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.Sastravi 150mg/37.5mg/200mg Film-coated Tablets
Sastravi is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.Sastravi 175mg/43.75mg/200mg Film-coated Tablets
Sastravi is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.Sastravi 200mg/50mg/200mg Film-coated Tablets
Sastravi is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.Sastravi 50mg/12.5mg/200mg Film-coated Tablets
Sastravi is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.Sastravi 75mg/18.75mg/200mg Film-coated Tablets
Sastravi is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.Route of administration: Oral
Molecule: carbidopa, levodopa, entacapone
Patients' opinions on Sastravi
Members using this Sastravi
Conditions related to this medication
Fact sheet
See the fact sheet
Tips and advice of the community